Zacks.com submits:
AstraZeneca (AZN) has received a pipeline setback with a mid-stage candidate failing to meet the primary endpoint of its study. The company was evaluating the effectiveness of Recentin (cediranib) in a phase II/III study (Horizon III) compared with Roche’s (RHHBY.PK) Avastin (bevacizumab), both in combination with chemotherapy in patients with first-line metastatic colorectal cancer (mCRC).
AstraZeneca is conducting another study with Recentin (Horizon II) in first-line mCRC. The effectiveness of the drug in combination with chemotherapy is being studied against chemotherapy alone. AstraZeneca is awaiting data from this study, which is expected shortly, before taking a final decision on its regulatory filing. In addition, results from a phase III study evaluating the effectiveness of Recentin in treating recurrent glioblastoma are expected in the first half of 2010.
Complete Story »